Green Cross (006280 KS): Hope Still Remains for the U.S. Approval of Blood Derivative Injection

Equity Bottom-Up

283 Views, 23 Jun 2022 16:45

EXECUTIVE SUMMARY

Green Cross (006280 KS) is expected to receive FDA approval for its immune globulin injection, once the agency conducts onsite inspection of its production facility.
After suffering in 2021, both blood products and vaccine business are back to double-digit growth path in Q1 2022. The company continues to win export orders for both of these.
Hunter syndrome and hemophilia treatments are the company’s new growth engines. Green Cross has received approval for its hunter syndrome treatment in China and Japan.

detail (4-minute read)

WHAT’S TRENDING

Insights